University of Illinois

Andaris Limited

Asrar B Malik

Yulia A Komarova

Mark Rosenblatt

Shahid Siddiqui

Stephen M Vogel

Zhenjia Wang

Jaehyung Cho

Uzma Saqib

Richard A Johnson

Jose S Pulido

Andrew Derek Sutton

Chinnaswamy Tiruppathi

Dolly Mehta

Kurt Bachmaier

Kaori Yamada

Kishore K Wary

Yidan Zhao

You-Yang Zhao

Nalin M Kumar

Beatrice Yue

A construct composed of a Kinesin-derived Angiogenesis Inhibitor peptide and one or more carrier moieties and/or stabilizing moieties is provided as are methods for inhibiting angiogenesis and treating a disease or condition characterized by excessive vascularity.

KIF13B-derived peptide and method of inhibiting angiogenesis

The present invention relates to peptides for inhibiting angiogenesis. The present invention also relates to methods of inhibiting angiogenesis and methods of treating disorders associated with VEGF-induced vascular permeability using the peptides of the invention.

Peptides for treating cancer

Disclosed are nanoparticle compositions comprising nanoparticles prepared from denatured, cross-linked albumin and a therapeutic agent for treating a neutrophil-mediated inflammation, and methods of treating neutrophil-mediated inflammation using the compositions.

Compositions and methods for diagnosing or treating neutrophil-mediated inflammatory disease

Peptides for inhibiting angiogenesis

Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.

Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Methods of treating endotoxin-mediated disorders are provided.

CBLB for treating endotoxin-mediated disorders

The present invention is a method for preparing a substantially pure population of endothelial progenitor cells wherein said cells express Flk-1, CD34, &#x3b1;&#x3b2;integrin fibronectin, and vWF and exhibit an adherent phenotype and methods for using the same to decrease the severity of lung injury, prevent pulmonary edema, restore endothelial barrier function, induce productive wound healing and angiogenesis, and increase survival rate in acute lung injury (ALI).

Selected endothelial progenitor cells and methods for use

The present application is directed to siRNA-based silencing of the type II receptor of TGF&#x3b2;. siRNAs that target this receptor abrogate the receptor protein and transcript, TGF&#x3b2;-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGF&#x3b2; type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body.

Silencing of TGF&#x3b2; type II receptor expression by siRNA

In various aspects and embodiments the invention provides methods and reagents for controlling gene expression, and for treating disorders and diseases. Embodiments provide methods and reagents specifically for the regulation of MLCK expression and for the use thereof in treating disorders and diseases. Various embodiments provide methods and reagents for specifically down regulating the expression of MLCK-L more efficiently than that of MLCK-S, and for the use thereof in treating disorders and diseases. Embodiments provide siNA for the same, particularly siRNAs. Various of the embodiments are useful for the treatment of inflammatory disorders and diseases, including, for one example in this regard, Asthma.

Modulation of MLCK-L expression and uses thereof

The present invention is directed to compositions based on myeloperoxidase amino acid sequence which may be used as therapeutic agents or as delivery vehicles for the delivery of other therapeutic agents.

Peptide carrier for drug delivery

Transcytosis of a physiologically-active agent that exerts its action following passage across endothelia, epithelia or mesothelia containing the GP60 receptor is enhanced by formulation with or conjugation to a transcytosis enhancer or vehicle selected from albumin and fragments thereof, anti-GP60 antibody and fragments thereof, GP60 peptide fragments, and PDI (protein disulphide isomerase) and fragments thereof.

Growing community of inventors

Chicago, IL, United States of America

Asrar B Malik